WACKER BIOSOLUTIONS

In 2019, WACKER BIOSOLUTIONS lifted its sales by 7.0 percent to €243.0 million (2018: €227.0 million). The main impetus came from higher volumes and positive exchange-rate effects. Lower prices, on the other hand, slowed sales growth. The division posted its biggest gains in biopharmaceuticals, where sales benefited from new production capacity in Amsterdam and high utilization rates at German sites. In regional terms, sales performance was good in the Americas and Asia.

At €31.1 million, EBITDA was significantly higher year over year (2018: €23.5 million). This increase was fueled by volume growth, by higher plant utilization for biopharmaceuticals and by an improved cost structure. The EBITDA margin was 12.8 percent (2018: 10.4 percent).

Capital expenditures declined year over year to €13.2 million (2018: €17.9 million), a decrease of 26.3 percent. One investment focus was the new biologics production plant in Amsterdam.

As of December 31, 2019, the division had 754 employees (Dec. 31, 2018: 709).